NASDAQ: CASI | 中文 | Contact Us

CASI News

CASI Hosts Nobel Laureate James P. Allison

September 10, 2019

CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at https://www.youtube.com/channel/UC5IBDAqhTqt5esL9r3dgQRQ.


Evomela Commercially Available In China

August 12, 2019

EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.

U.S. FDA-Approved Products In-Licensed for the Greater China Region

Evomela®

Multiple Myeloma

Zevalin®

Non-Hodgkin's Lymphoma

Marqibo®

Acute Lymphoblastic Leukemia

Pre-Clinical Drug Candidates

CID-103

Multiple Myeloma

CNTC19

Hematological Malignancies
Learn more about our product pipeline